Sign in

CIK 0001652130 · Large accelerated filer

Intellia Therapeutics, Inc.

Sign in to watch
Ticker
NTLA
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
364785571
Phone
857-285-6200
Business address
400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
  1. 8-K Event Results of operations
  2. 8-K Event Material agreement · New debt or obligation
  3. 4 Planned sale Director sold 265 shares at $9.97 ($2,642)
  4. 3 Insider Initial Statement of Ownership
  5. 8-K Event Results of operations · Exit or restructuring costs · Executive or director change · Regulation FD disclosure · Other events
  6. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  7. 4 Open-market sale VP, Chief Accounting Officer sold 1,372 shares at $12.18 ($16,711)
  8. 4 Open-market sale EVP, General Counsel sold 7,074 shares at $12.18 ($86,161)
  9. 4 Open-market sale EVP, Chief Medical Officer sold 9,557 shares at $12.18 ($116,404)
  10. 4 Open-market sale EVP, Chief Business Officer sold 6,502 shares at $12.18 ($79,194)
  11. 4 Open-market sale President and CEO sold 26,807 shares at $12.18 ($326,509)
  12. 4 Open-market sale EVP, Chief Scientific Officer sold 8,966 shares at $12.18 ($109,206)
  13. 4 Open-market sale EVP, Chief Technical Officer sold 7,978 shares at an average $12.17 ($97,089)
  14. 4 Option exercise EVP, Chief Medical Officer acquired 3,189 shares (option exercise)
  15. 4 Option exercise President and CEO acquired 7,850 shares (option exercise)
  16. 4 Option exercise EVP, Chief Scientific Officer acquired 3,500 shares (option exercise)
  17. 8-K Event Regulation FD disclosure · Other events
  18. 10-Q Report Quarterly Report
  19. 8-K Event Results of operations
  20. 8-K Event Regulation FD disclosure · Other events

Page 7 of 37 · 725 filings